RNF4 and acute myeloid leukemia: Since the efficiency of PROTACs can be cell-type specific, we validated our compounds in two AML cell lines, NB-4 and OCI-AML2, but again we were unable to detect degradation of RNF4 upon exposure to the CCW16-based degraders at different concentrations and treatment times (Fig. EV2E,F).